JPS63183563A - 2-quinolylmethyl=sulfide derivative and production thereof - Google Patents
2-quinolylmethyl=sulfide derivative and production thereofInfo
- Publication number
- JPS63183563A JPS63183563A JP19743587A JP19743587A JPS63183563A JP S63183563 A JPS63183563 A JP S63183563A JP 19743587 A JP19743587 A JP 19743587A JP 19743587 A JP19743587 A JP 19743587A JP S63183563 A JPS63183563 A JP S63183563A
- Authority
- JP
- Japan
- Prior art keywords
- quinoline
- compound
- quinolylmethyl
- formula
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- -1 2-quinolylmethyl Chemical group 0.000 title abstract description 4
- 150000003568 thioethers Chemical class 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000002798 polar solvent Substances 0.000 claims abstract description 8
- DDEAEWMDOSXKBX-UHFFFAOYSA-N 2-(chloromethyl)quinoline Chemical compound C1=CC=CC2=NC(CCl)=CC=C21 DDEAEWMDOSXKBX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract 2
- NINCMKJQHKDMPH-UHFFFAOYSA-N 2-methylsulfanylquinoline Chemical class C1=CC=CC2=NC(SC)=CC=C21 NINCMKJQHKDMPH-UHFFFAOYSA-N 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 abstract description 56
- 239000003814 drug Substances 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 abstract description 5
- 230000009090 positive inotropic effect Effects 0.000 abstract description 4
- 230000003501 anti-edematous effect Effects 0.000 abstract description 3
- 101150056637 Hrh2 gene Proteins 0.000 abstract description 2
- 210000004165 myocardium Anatomy 0.000 abstract description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 150000004763 sulfides Chemical class 0.000 abstract 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 134
- 230000000694 effects Effects 0.000 description 22
- 239000013078 crystal Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- 238000000921 elemental analysis Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 230000000704 physical effect Effects 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- WDETYCRYUBGKCE-UHFFFAOYSA-N 2-(chloromethyl)quinolin-1-ium;chloride Chemical compound Cl.C1=CC=CC2=NC(CCl)=CC=C21 WDETYCRYUBGKCE-UHFFFAOYSA-N 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- VHNILDKAFINLSQ-UHFFFAOYSA-N 1-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]piperazine-2,5-dione Chemical compound NCC=1C(CC(C)C)=NC2=CC=C(N3C(CNC(=O)C3)=O)C=C2C=1C1=CC=C(C)C=C1 VHNILDKAFINLSQ-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- PDQAZBWRQCGBEV-UHFFFAOYSA-N Ethylenethiourea Chemical compound S=C1NCCN1 PDQAZBWRQCGBEV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 2
- 229960002105 amrinone Drugs 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- DDMGAAYEUNWXSI-XVSDJDOKSA-M sodium;(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound [Na+].CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O DDMGAAYEUNWXSI-XVSDJDOKSA-M 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- PTVZQOAHCSKAAS-UHFFFAOYSA-N 4-methyl-3-thiosemicarbazide Chemical compound CNC(=S)NN PTVZQOAHCSKAAS-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- VLCDUOXHFNUCKK-UHFFFAOYSA-N N,N'-Dimethylthiourea Chemical compound CNC(=S)NC VLCDUOXHFNUCKK-UHFFFAOYSA-N 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- HTKFORQRBXIQHD-UHFFFAOYSA-N allylthiourea Chemical compound NC(=S)NCC=C HTKFORQRBXIQHD-UHFFFAOYSA-N 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔技術分野〕
本発明は2−キノリルメチル−スルフィド誘導体及びそ
の製造方法に関する。DETAILED DESCRIPTION OF THE INVENTION [Technical Field] The present invention relates to a 2-quinolylmethyl-sulfide derivative and a method for producing the same.
本発明の化合物は、心筋に対する強力な陽性変力作用、
血小板凝集作用、抗浮腫作用、H2レセプター阻害作用
等を有し、医薬品として極めて重要なものである。また
、本発明化合物の製造法は、市場で容易に入手可能でし
かも安価な2−クロロメチルキノリンと、チオ尿素誘導
体を、極性溶媒中、単に室温で攪拌するという単純な製
造方法に関する。The compounds of the invention have a strong positive inotropic effect on the myocardium,
It has platelet aggregating effects, anti-edema effects, H2 receptor inhibiting effects, etc., and is extremely important as a medicine. Furthermore, the method for producing the compound of the present invention relates to a simple production method in which 2-chloromethylquinoline, which is easily available on the market and is inexpensive, and a thiourea derivative are simply stirred at room temperature in a polar solvent.
本発明の目的は、新規な2−キノリルメチル−スルフィ
ド誘導体及びその製造方法を提供することにある。An object of the present invention is to provide a novel 2-quinolylmethyl-sulfide derivative and a method for producing the same.
上記の目的を達成するため本発明は以下の構成からなる
。In order to achieve the above object, the present invention consists of the following configuration.
(1)一般式(■):
〔式中R1は、
■
NR’
−C−NR’R’
(ただし、R2は水素又は低級アルキル基、R3及びR
4は飽和又は不飽和の低級アルキル基、アミノ基又はア
リール基である)を示す〕の2−キノリルメチル−スル
フィド誘導体。(1) General formula (■): [In the formula, R1 is ■ NR'-C-NR'R' (wherein, R2 is hydrogen or a lower alkyl group, R3 and R
4 is a saturated or unsaturated lower alkyl group, amino group or aryl group].
(2)2−クロロメチルキノリンと、
一般式(III)
HR2
(ただし、R2は水素又は低級アルキル基、R3及びR
4は飽和又は不飽和の低級アルキル基、アミノ基又はア
リール基である)の化合物とを極性溶媒中で反応せしめ
ることを特徴とする、2−キノリルメチル−スルフィド
誘導体の製造方法。(2) 2-chloromethylquinoline and general formula (III) HR2 (wherein R2 is hydrogen or a lower alkyl group, R3 and R
4 is a saturated or unsaturated lower alkyl group, amino group or aryl group) in a polar solvent.
(3)2−クロロメチルキノリンと、
一般式(IV)
(式中R4は−Nll−CH,−C11,−1−3−C
=N−を示す。)NH2
の化合物とを極性溶媒中で反応せしめることを特徴とす
る、2−キノリルメチル−スルフィド誘導体の製造方法
。(3) 2-chloromethylquinoline and general formula (IV) (wherein R4 is -Nll-CH, -C11, -1-3-C
=N−. ) A method for producing a 2-quinolylmethyl-sulfide derivative, which comprises reacting a 2-quinolylmethyl-sulfide derivative with a compound of NH2 in a polar solvent.
以下、本発明の化合物の製造方法を実施例により例示的
に説明する。Hereinafter, the method for producing the compound of the present invention will be illustratively explained using Examples.
ただし、これらは単に説明の便宜上示すものであり、本
発明はこれらの具体例に特定されるものではない。However, these are merely shown for convenience of explanation, and the present invention is not limited to these specific examples.
実施例1
1−メチル−2−(2−キノリルメチル)イソチオ尿素
二塩酸塩(化合物(■))の製造方法。Example 1 Method for producing 1-methyl-2-(2-quinolylmethyl)isothiourea dihydrochloride (compound (■)).
〉 自 恍
″′$ 贈
\ セ
自 も
; 9
2−(クロロメチル)キノリン塩酸塩2.14 g(0
,01モル)とN−メチルチオ尿素0.9g(0,01
(−ル)のメタノール(30+y+Il)溶液を、室温
にて5分間攪拌後、室温にて減圧濃縮し、褐色油状物を
得た。これにアセトニトリルを加え、析出した結晶を濾
取し、化合物(V) 2.0.8 g(収率68.4%
)を得た。〉 2-(chloromethyl)quinoline hydrochloride 2.14 g (0
,01 mol) and 0.9 g (0,01 mol) of N-methylthiourea
A solution of (-L) in methanol (30+y+Il) was stirred at room temperature for 5 minutes and then concentrated under reduced pressure at room temperature to obtain a brown oil. Acetonitrile was added to this, the precipitated crystals were collected by filtration, and 2.0.8 g of compound (V) (yield 68.4%) was obtained.
) was obtained.
融点 167〜172℃(エタノール)、無色針状晶。 Melting point: 167-172°C (ethanol), colorless needle crystals.
元素分析 C1□H,、N3S・2HCj2計算値:C
,47J7; l(,4,97; N、13.81
゜実測値:C,47J7; H,4,80; N、
14.17゜’ H−NMR(DMSOJs) δ:
2.97(3H,d、 C113)、 5.04(2
H。Elemental analysis C1□H,, N3S・2HCj2 calculated value: C
,47J7; l(,4,97; N, 13.81
゜Actual measurement value: C, 47J7; H, 4, 80; N,
14.17゜' H-NMR (DMSOJs) δ:
2.97 (3H, d, C113), 5.04 (2
H.
S、 CH2−)、 7.538.76(6H,m
、 キノリンH)、 9.0L−10、61(4tl
、 broad、 =NH,−NH−、2flC1、0
20置換により消失)。S, CH2-), 7.538.76 (6H, m
, quinoline H), 9.0L-10, 61 (4tl
, broad, =NH, -NH-, 2flC1,0
20 substitutions).
” C−NMR(DMSO−d、)δ: 30.9 (
q、 CH3) 、 34.7 (t、 −CH2−)
。"C-NMR (DMSO-d,) δ: 30.9 (
q, CH3), 34.7 (t, -CH2-)
.
121、9 (d、キノリンC3) 、 124.1
(S、キノリンCl0)。121,9 (d, quinoline C3), 124.1
(S, quinoline Cl0).
127、2 (S、 d、キノリンC9,C5)、 1
28.4(d、 d、 キノリンC6,C7)、
132.4(d、キノリンC8) 、 141.9 (
d、、キノリンC4) 、 155.2 (s、キノリ
ンC2)、 165.0(s、 〉C=Ntl) 。127, 2 (S, d, quinoline C9, C5), 1
28.4 (d, d, quinoline C6, C7),
132.4 (d, quinoline C8), 141.9 (
d, quinoline C4), 155.2 (s, quinoline C2), 165.0 (s, 〉C=Ntl).
I Rv ’ cn+−’ : 2940.2460
.1920.16’50.1615.760゜実施例2
1.3−ジメチル−2−(2−キノリルメチル)イソチ
オ尿素二塩酸塩(化合物(■))の製造方法。I Rv'cn+-': 2940.2460
.. 1920.16'50.1615.760° Example 2 Method for producing 1.3-dimethyl-2-(2-quinolylmethyl)isothiourea dihydrochloride (compound (■)).
2−(クロロメチル)キノリン塩酸塩6.42 g(0
,03モル)と1.3−ジメチルチオ尿素3.13g(
0,03モル)のメタノール(40mAり溶液を、実施
例1と同様に処理し、褐色油状物を得た。これに、クロ
ロホルムを加え、析出した結晶を濾取し化合物(Vl)
6.60g(収率69.1%)を得た。2-(chloromethyl)quinoline hydrochloride 6.42 g (0
,03 mol) and 3.13 g of 1,3-dimethylthiourea (
A solution of 0.03 mol) in methanol (at 40 mA) was treated in the same manner as in Example 1 to obtain a brown oil.Chloroform was added to this, and the precipitated crystals were collected by filtration to obtain compound (Vl).
6.60 g (yield 69.1%) was obtained.
融点 165〜171t’(エタノール)、無色針状晶
。Melting point 165-171t' (ethanol), colorless needle crystals.
元素分析 C138I5N3S・21(Cl計算値:C
,49,06; H,5,38; N、13.20.
CI、 22.28゜実測値:C,49,07; H,
5,40,N、13.30. CI2,22.12゜’
H−NMR(DMSO−d6) δ: 3.03
(611,d、 −NH−CH3,−N−CH3)、
5.22 (2H,S、 Ctl2−) 、 7.5
2−9.03 (611,m、キノリン)l)、 9.
62−10.84 (3tl、 broad、 −JJ
H−Ctl、、 2H[l’ It 、 D2[]置換
により消失)。Elemental analysis C138I5N3S・21 (Cl calculated value: C
, 49,06; H, 5,38; N, 13.20.
CI, 22.28° Actual value: C, 49,07; H,
5,40,N,13.30. CI2, 22.12゜'
H-NMR (DMSO-d6) δ: 3.03
(611, d, -NH-CH3, -N-CH3),
5.22 (2H,S, Ctl2-), 7.5
2-9.03 (611,m, quinoline)l), 9.
62-10.84 (3tl, broad, -JJ
H-Ctl, 2H[l'It, disappeared by D2[] substitution).
” C−NMR(DMSO−d、) δ: 31.1
(Q、 −NH−CH3,=N−CH,)。"C-NMR (DMSO-d,) δ: 31.1
(Q, -NH-CH3,=N-CH,).
35、2 (t、 −c++2−) 、 121.9
(d、キノリンC3)、 124.9 (d、キノリン
C6) 、 127.2 (s、キノリンCl0)、
128.0 (d、 キノリンC5) 、 128.
4 (d、キノリンC7) 、 132.2 (d、キ
ノリンC8)、 141.3(d、キノリンC4) 、
143.1 (s、キノリンC9)。35, 2 (t, -c++2-), 121.9
(d, quinoline C3), 124.9 (d, quinoline C6), 127.2 (s, quinoline Cl0),
128.0 (d, quinoline C5), 128.
4 (d, quinoline C7), 132.2 (d, quinoline C8), 141.3 (d, quinoline C4),
143.1 (s, quinoline C9).
155、0 (s、キノリンC2) 、 165.6
(s、 CH3−N−c−NH−CH3) 。155,0 (s, quinoline C2), 165.6
(s, CH3-N-c-NH-CH3).
I Rv cm−’ : 2970.2400.1
920.1610 。I Rv cm-': 2970.2400.1
920.1610.
実施例3
3−(2−キノリルメチル)イソチオセミカルバジドニ
塩酸塩(化合物(■)の製造方法。Example 3 3-(2-quinolylmethyl)isothiosemicarbazidonihydrochloride (method for producing compound (■)).
2−(クロロメチル)キノリン塩酸塩8.56 g(0
,04モル)と、チオセミカルバジド3.64 g(0
,04モル)のエタノール(40ml)溶液を、3時間
加熱還流した。これを放冷し、析出した結晶を濾取し、
化合物(■)8.42g(収率69.0%)を得た。2-(chloromethyl)quinoline hydrochloride 8.56 g (0
,04 mol) and thiosemicarbazide 3.64 g (0
, 04 mol) in ethanol (40 ml) was heated under reflux for 3 hours. This was allowed to cool, and the precipitated crystals were collected by filtration.
8.42 g (yield 69.0%) of compound (■) was obtained.
融点 154〜158℃(エタノール)、無色プリズム
。Melting point 154-158°C (ethanol), colorless prism.
元素分析 C++)l+J4S・211CA計算値:
C,43,28,H,4,62; N、 1g、 36
゜実測値: C,43,46; )I、 4.69;
N、 18.51゜’H−NMR(DMSO−ds)
δ: 4.94(2N、 S、 −CI(2−)、
7.56−9.10 (8)1. m、 D20置換
により一部消失)、 ’9.10−10.68(4H,
broad、ロ、0置換により消失)。Elemental analysis C++)l+J4S・211CA calculated value:
C, 43,28, H, 4,62; N, 1g, 36
゜Actual measurement value: C, 43, 46; ) I, 4.69;
N, 18.51゜'H-NMR (DMSO-ds)
δ: 4.94 (2N, S, -CI(2-),
7.56-9.10 (8)1. m, partially disappeared due to D20 substitution), '9.10-10.68 (4H,
broad, b, disappeared by 0 substitution).
” C−NMR(DMSO−d、) δ: 32.1
(t、 −C1j2−) 、 120.9 (d。"C-NMR (DMSO-d,) δ: 32.1
(t, -C1j2-), 120.9 (d.
キノリ7C3) 、 122.7 (d、キノリ7C6
)、 127.1(s、キノリンCl0)、 128.
8(d、 d、 キノリンC5,C7) 、 134
. El <s。Kinori 7C3), 122.7 (d, Kinori 7C6
), 127.1(s, quinoline Cl0), 128.
8 (d, d, quinoline C5, C7), 134
.. El<s.
キノリンC9>、 138.0 (d、キノリンcg>
、 145.2 <d、キノリンC4) 、 156.
2 (s、キノリン[2)、 161.8(s、ンC
−N If ) 。Quinoline C9>, 138.0 (d, quinoline cg>
, 145.2 <d, quinoline C4) , 156.
2 (s, quinoline [2), 161.8 (s, nC
-NIf).
実施例4
4−メチル−3−(2−キノリルメチル)インチオセミ
カルバジドニ塩酸塩(化合物(■))の製造方法。Example 4 Method for producing 4-methyl-3-(2-quinolylmethyl)inthiosemicarbazidonihydrochloride (compound (■)).
(0,03モル)と、4−メチルチオセミカルバジド3
.15 g (0,03%ル)にメタノール(40mj
! )を加え、30℃で溶解し、室温で20分間攪拌し
た。この溶液を室温にて減圧濃縮し1、褐色油状物を得
た。これにエタノールを加え、析出した結晶を濾取し、
化合物(■)5.41g(収率56.5%)を得た。(0.03 mol) and 4-methylthiosemicarbazide 3
.. 15 g (0.03%) of methanol (40 mj
! ) was added, dissolved at 30°C, and stirred at room temperature for 20 minutes. This solution was concentrated under reduced pressure at room temperature to obtain a brown oil. Add ethanol to this, collect the precipitated crystals by filtration,
5.41 g (yield 56.5%) of compound (■) was obtained.
融点 175〜178℃(エタノール)、無色針状晶。 Melting point: 175-178°C (ethanol), colorless needle crystals.
元素分析 Cl2F114N4S・2HCj1!計算値
: C,45,14; H,5,05; N、 17.
55゜実測値: C,45,21;H,4,87; N
、 17.10゜’ H−NMR(DMSO−d6)
δ: 2’、 90(3)1. S、 C)Is)
、 4.94(2H。Elemental analysis Cl2F114N4S・2HCj1! Calculated values: C, 45,14; H, 5,05; N, 17.
55° Actual measurement: C, 45, 21; H, 4, 87; N
, 17.10゜' H-NMR (DMSO-d6)
δ: 2', 90(3)1. S, C)Is)
, 4.94 (2H.
S、 −CI(3−) 、 6.24 (broad、
−NH−N)12.2H’CI 、 020置換によ
り消失)、 7.47−9.22 (6)1. m、
キノリ7H)。S, -CI(3-), 6.24 (broad,
-NH-N)12.2H'CI, disappeared by 020 substitution), 7.47-9.22 (6)1. m,
Kinori 7H).
”C−NMR(DMSO−66) δ: 30.1
(Q、 CH,)、 33.9 (t。"C-NMR (DMSO-66) δ: 30.1
(Q, CH,), 33.9 (t.
−CH2−) 、 122.2 (d、 キノリンC
3) 、 123.6 (d、キノリンC6)、 12
7.2 (S、キノリンC’lO) 、 128.5
(d、 d、 キノリンC5,C7) 、 132.
8 (d’、 キノリンC8)、 141.0(S、
キノリンC9) 、 142.7 (d、キノリンC4
) 、 155.8 (S、キノリンC2)。-CH2-), 122.2 (d, quinoline C
3), 123.6 (d, quinoline C6), 12
7.2 (S, quinoline C'lO), 128.5
(d, d, quinoline C5, C7), 132.
8 (d', quinoline C8), 141.0 (S,
quinoline C9), 142.7 (d, quinoline C4
), 155.8 (S, quinoline C2).
165.0(S、 〉C=N−) 。165.0 (S,〉C=N-) .
I Rv cm−’ : 3300.3200.
2870.2400.1975゜1650、750゜
実施例5
■−アリルー2− (2−キノリルメチル)イソチオ尿
素二塩酸塩(化合物(■))の製造方法。I Rv cm-': 3300.3200.
2870.2400.1975°1650, 750°Example 5 ■-Method for producing aryl-2-(2-quinolylmethyl)isothiourea dihydrochloride (compound (■)).
2−(クロロメチル)キノリン塩酸塩6.42 g(0
,03モル)と、1−アリル−2−チオ尿素3.48g
(0,03(4)のメタ7−ル(40mf)溶液を、
実施例1と同様に処理し、褐色結晶を得た。これをエタ
ノールで濾取し、次いで含水アセトンにて洗浄し、化合
物(IX)6.24g(収率63.0%)を得た。2-(chloromethyl)quinoline hydrochloride 6.42 g (0
,03 mol) and 3.48 g of 1-allyl-2-thiourea.
(0,03(4) methanol (40mf) solution,
It was treated in the same manner as in Example 1 to obtain brown crystals. This was collected by filtration with ethanol and then washed with aqueous acetone to obtain 6.24 g (yield 63.0%) of compound (IX).
融点 165〜171℃(エタノール)、無色針状晶。 Melting point: 165-171°C (ethanol), colorless needle crystals.
元素分析 C14)115N3S・2HC1計算値:C
,50,91; H,5,18; N、L2.72;
([,21,47゜実測値:C,50,64; H,5
,20; N、12.61; (1!、21.31゜’
H−NMR(DMSO−d、) δ: 4.11
(2H,bt、 mNII−C川、−)。Elemental analysis C14) 115N3S・2HC1 calculated value: C
,50,91; H,5,18; N, L2.72;
([, 21, 47° Actual value: C, 50, 64; H, 5
,20; N, 12.61; (1!, 21.31°'
H-NMR (DMSO-d,) δ: 4.11
(2H, bt, mNII-C river, -).
4、86−5.44 (4H,m、 −CH=CH2,
−CH2−3−)、 6.82 (broad) 。4,86-5.44 (4H,m, -CH=CH2,
-CH2-3-), 6.82 (broad).
7、46−8.98 (6H,m、 キノリンH)、
9.30−10.95 (311゜broad )。7, 46-8.98 (6H, m, quinoline H),
9.30-10.95 (311°broad).
” C−NMR(DMSO−d、)δ: 35.3 (
t、 −CH2−6−) 、 46.1 (t。"C-NMR (DMSO-d,) δ: 35.3 (
t, -CH2-6-), 46.1 (t.
−NH−CH2−) 、 118.3 (t、 −Cl
l=C11,、) 、、122.3 (d、 キノリ
ンC3) 、 125.7 (d、キノリンC6) 、
127.7 (S、キノリンCl0)。-NH-CH2-), 118.3 (t, -Cl
l=C11,) , 122.3 (d, quinoline C3) , 125.7 (d, quinoline C6) ,
127.7 (S, quinoline Cl0).
128、6 (d、キノリンC5)、 128.9 (
d、キノリンC7)。128,6 (d, quinoline C5), 128.9 (
d, quinoline C7).
131.5(d、キノリンCB) 、 132.5 (
d、キノリンC4) 、 1.41.6(d、 −CH
=CH1,) 、 143.9 (S、キノリンC9)
、 156.1 (S、キノリンC2)、 165.8
(S、 NH=Cり)。131.5 (d, quinoline CB), 132.5 (
d, quinoline C4), 1.41.6(d, -CH
=CH1,), 143.9 (S, quinoline C9)
, 156.1 (S, quinoline C2), 165.8
(S, NH=Cri).
実施例6
1−フェニル−2−(2−キノリルメチル)イソチオ尿
素二塩酸塩(化合物(X)の製造方法。Example 6 1-phenyl-2-(2-quinolylmethyl)isothiourea dihydrochloride (method for producing compound (X)).
−7 \ セ
命 も
+
#4
2−(クロロメチル)キノリン塩酸塩5.35 g(0
,025モル)と、1−フェニル−2−チオ尿素3.8
g(0,025モル)のアセトン(40mjり一メタノ
ール(10mj2>混合溶液を、実施例1と同様に処理
し、褐色油状物を得た。これに、クロロホルムを加え析
出した結晶を濾取し、化合物(X)7.16g(収率7
8.3%)を得た。-7 \ Semeimo+ #4 2-(chloromethyl)quinoline hydrochloride 5.35 g (0
,025 mol) and 3.8 mol of 1-phenyl-2-thiourea.
A mixed solution of g (0,025 mol) of acetone (40 mj) and methanol (10 mj2) was treated in the same manner as in Example 1 to obtain a brown oil.Chloroform was added to this and the precipitated crystals were collected by filtration. , compound (X) 7.16 g (yield 7
8.3%).
融点 156〜164℃(エタノール)、無色プリズム
。Melting point 156-164°C (ethanol), colorless prism.
元素分析 Cr、H+5N3S・2HC1計算値:C,
55,74; H,4,68; N、11.47゜実測
値: C,55,88; H,4,71; N、 11
.54゜’ H−NMR(DMSO−d6) δ:
5.31 (2H,s、 CH2)、 7.44(5
H,s、フェニルH) 、 7.37−9.01 (6
H,m、キノリンH)。Elemental analysis Cr, H+5N3S・2HC1 calculated value: C,
55,74; H, 4,68; N, 11.47° Actual measurement: C, 55,88; H, 4,71; N, 11
.. 54゜' H-NMR (DMSO-d6) δ:
5.31 (2H,s, CH2), 7.44 (5
H, s, phenyl H), 7.37-9.01 (6
H, m, quinoline H).
9、99 (411,broad、 =NH,−NH−
、2HCj! )。9,99 (411,broad, =NH, -NH-
, 2HCj! ).
” C−NMR(DMSO−d6) δ: 35.1
(t、 −CH2−) 、 122.0 (d。”C-NMR (DMSO-d6) δ: 35.1
(t, -CH2-), 122.0 (d.
キノリンc3)、 124.6(d、キノリンC6)
、 125.3 (d、 s、フェニルC2,C6,キ
ノリンCIO,)、 127.2 (d、フェニルC4
)。quinoline c3), 124.6 (d, quinoline C6)
, 125.3 (d, s, phenyl C2, C6, quinoline CIO,), 127.2 (d, phenyl C4
).
128、1 (d、キノリンC5) 、 128.5
(d、キノリンC7)。128,1 (d, quinoline C5), 128.5
(d, quinoline C7).
129、7(d、 7 、 ニルC3,C5)、 13
2.3(d、 キ/ !J 7C8)。129, 7 (d, 7, nil C3, C5), 13
2.3 (d, Ki/!J 7C8).
135、 Hs、 −y エールCI)、 141.6
(s、キノリンC4)、 142.7(s、 キノリ
7C9)、 155.1 (s、キノリ7C2)、 1
67、4(s。135, Hs, -y Yale CI), 141.6
(s, Quinoline C4), 142.7 (s, Quinoline 7C9), 155.1 (s, Quinoline 7C2), 1
67, 4 (s.
>c=NH,>
1600、1575.1540.1515.1380.
835゜実施例7
2−イミダシリン−2−イル−2−キノリルメチルース
ルフィドニ塩酸塩(化合物(XI))の製造方法。>c=NH, >1600, 1575.1540.1515.1380.
835° Example 7 Method for producing 2-imidacillin-2-yl-2-quinolylmethyl-sulfide dihydrochloride (compound (XI)).
二 ニ
ー コ亨
1 区
+
…
2−(クロロメチル)キノリン塩酸塩2.14 g(0
,01モル)と、エチレンチオ尿素(2−イミダゾリジ
ンチオン)1.02g(0,01モル)をメタノール(
15mjりに30℃で溶解し、室温にて一時間攪拌した
。これを室温にて減圧濃縮し、褐色油状物を得た。これ
にエタノールを加え、析出した結晶を濾取し、化合物(
XI) 2.13g (収率67.4%)を得た。2-(chloromethyl)quinoline hydrochloride 2.14 g (0
,01 mol) and 1.02 g (0.01 mol) of ethylenethiourea (2-imidazolidinethione) in methanol (
The mixture was dissolved in 15 mj at 30°C and stirred at room temperature for 1 hour. This was concentrated under reduced pressure at room temperature to obtain a brown oil. Ethanol was added to this, the precipitated crystals were collected by filtration, and the compound (
XI) 2.13 g (yield 67.4%) was obtained.
融点 191〜192℃(エタノール)、無色針状晶。 Melting point: 191-192°C (ethanol), colorless needle crystals.
元素分析 CrsH+3N3S・2HC1計算値:C,
49,37; H,4,78: N、13.29; (
J!、22.42゜実測値:C,49,55; H,4
,76; N、13.45. Cjl!、22.15゜
’ H−NMR(DMSO−d6) δ: 3.90
(4H,S、イミダシリンメチレン)、 5.16
(2H,s、 S C112−) 、 ’5.76 (
broad。Elemental analysis CrsH+3N3S・2HC1 calculated value: C,
49,37; H, 4,78: N, 13.29; (
J! , 22.42° Actual value: C, 49,55; H, 4
, 76; N, 13.45. Cjl! , 22.15゜' H-NMR (DMSO-d6) δ: 3.90
(4H,S, imidacillin methylene), 5.16
(2H,s, S C112-), '5.76 (
broad.
2HC1)、 7.41−8.90 (6t1. m、
キノリンH)、 10.93 (Ill。2HC1), 7.41-8.90 (6t1.m,
Quinoline H), 10.93 (Ill.
broad)、 〉NH)。broad),〉NH).
”C−NMR(DMSO−ds)δ: 35.l(t、
5−C112)、 45.2(i、イミダシリンメチ
レン)、 121.6(d、 キノリンC3)。"C-NMR (DMSO-ds) δ: 35.l(t,
5-C112), 45.2 (i, imidacillin methylene), 121.6 (d, quinoline C3).
125、4 (d、キノリンC6)、 127.2(s
、キノリンCl0)。125,4 (d, quinoline C6), 127.2 (s
, quinoline Cl0).
127.9 (d、キノリンC5) 、 128.4
(d、キノリンC7)。127.9 (d, quinoline C5), 128.4
(d, quinoline C7).
131.9(d、キノリンc8) 、 140.7 (
d、キノリンC4)。131.9 (d, quinoline c8), 140.7 (
d, quinoline C4).
143、6 (S、キノリンC9) 、 154.8
(s、キノリンC2)。143,6 (S, quinoline C9), 154.8
(s, quinoline C2).
168、3 (s、 −N=C−NH−) 。168, 3 (s, -N=C-NH-).
1540、1520.1400.1265.765 。1540, 1520.1400.1265.765.
実施例8
2((5−アミノ)−1,3,4−チアジアゾイル)−
2−キノリルメチル=スルアイドニ塩酸塩(化合物(X
II))の製造方法。Example 8 2((5-amino)-1,3,4-thiadiazoyl)-
2-quinolylmethyl sulfaidonihydrochloride (compound (X
II)) Manufacturing method.
一ト!
$ 自
十
目
2−(クロロメチル)キノリン塩酸塩6.42 g(0
,03モル)と、2−アミノ−5−メルカプト−1,3
,4−チアジアゾール4.OOg(0,03モル)に、
メタノール(40mj’)を加え、30℃で溶解し、室
温にて5分間攪拌後、室温にて減圧濃縮し、褐色油状物
を得た。これにエタノールを加え、析出した結晶を濾取
し、化合物(XI)9.43g(収率90.5%)を得
た。Itto! $ Jijumoku 2-(chloromethyl)quinoline hydrochloride 6.42 g (0
,03 mol) and 2-amino-5-mercapto-1,3
,4-thiadiazole4. OOg (0.03 mol),
Methanol (40 mj') was added and dissolved at 30°C, stirred at room temperature for 5 minutes, and concentrated under reduced pressure at room temperature to obtain a brown oil. Ethanol was added to this, and the precipitated crystals were collected by filtration to obtain 9.43 g (yield: 90.5%) of compound (XI).
融点 177〜182℃(エタノール)、無色プリズム
。Melting point 177-182°C (ethanol), colorless prism.
元素分析 c、2H,oN4S ・2HC1計算値:C
,41,50; H,3,48; N、16.13;
C1,20,42゜実測値:C,41,20; H,3
,52; N、15.94; [4!、20.22゜’
)I−NMR(口MSO−d6) δ :5
.01(2H,S、−CH2)、 7.46−− 9
.20(6H,m キノリンH) 、 9.48 (4
H,broad、 −NH2゜2HCjり。Elemental analysis c, 2H, oN4S ・2HC1 calculated value: C
,41,50; H,3,48; N,16.13;
C1, 20, 42° Actual value: C, 41, 20; H, 3
,52; N, 15.94; [4! , 20.22゜'
)I-NMR (MSO-d6) δ:5
.. 01 (2H, S, -CH2), 7.46-- 9
.. 20 (6H, m quinoline H), 9.48 (4
H, broad, -NH2゜2HCjri.
”C−NMR(口MSO−ds) δ : 36
.1 (t、−CH2−)、122.3 (d。”C-NMR (MSO-ds) δ: 36
.. 1 (t, -CH2-), 122.3 (d.
d、キノリンC3、キノリンC6) 、 127.2
(s、キノリンCl0) 、 128.8 (d、 d
、 キノリンC5、キノリンC7)。d, quinoline C3, quinoline C6), 127.2
(s, quinoline Cl0), 128.8 (d, d
, quinoline C5, quinoline C7).
133、5 (d、キノリン[:8) 、 139.7
(s、キノリンc9)。133,5 (d, quinoline [:8), 139.7
(s, quinoline c9).
1540、1400.1380.700゜実施例9
1.1−ジフェニル−2−(2−キノリルメチル)イソ
チオ尿素二塩酸塩(化合物(XIIr))の製造方法。1540, 1400.1380.700° Example 9 1. Method for producing 1-diphenyl-2-(2-quinolylmethyl)isothiourea dihydrochloride (compound (XIIr)).
2−クロロメチルキノリン塩酸塩2. ! 4 g(0
,01モル)と、1.1−ジフェニル−2−チオ尿素2
.28g(0,01モル)を50〜60℃で8時間攪拌
後、室温にて減圧濃縮し、無色結晶を得た。これにエタ
ノールを加え、析出した結晶を濾取し、1.1−ジフェ
ニル−2−(2−キノリルメチル)イソチオ尿素二塩酸
塩(化合物(XIII))3.18g(収率72%)を
得た。2-Chloromethylquinoline hydrochloride 2. ! 4 g (0
,01 mol) and 1,1-diphenyl-2-thiourea2
.. After stirring 28 g (0.01 mol) at 50 to 60° C. for 8 hours, the mixture was concentrated under reduced pressure at room temperature to obtain colorless crystals. Ethanol was added to this, and the precipitated crystals were collected by filtration to obtain 3.18 g (yield 72%) of 1.1-diphenyl-2-(2-quinolylmethyl)isothiourea dihydrochloride (compound (XIII)). .
融点 186〜189℃(エタノール)、無色プリズム
。Melting point 186-189°C (ethanol), colorless prism.
元素分析 C2J1sNss・2HCA計算値:C,6
2,44; H,4,78; N、9.50゜実測値:
C,62,41; H,4,82; N、9.52゜’
H−NMR(DMSO−d s) δ: 5.0
8 (2H,S) 、 6.52 (21(、br)。Elemental analysis C2J1sNss・2HCA calculated value: C, 6
2,44; H, 4,78; N, 9.50°Actual measurement:
C, 62,41; H, 4,82; N, 9.52°'
H-NMR (DMSO-ds) δ: 5.0
8 (2H,S), 6.52 (21(,br).
7、42−8.12(15ft、 m)、 8.63
(IH,d)、 9.40(IH,br)。7, 42-8.12 (15ft, m), 8.63
(IH, d), 9.40 (IH, br).
” C−NMR(DMSO−d、)δ: 37.0(t
)、 121.9(d)、 125.6(d)。"C-NMR (DMSO-d,) δ: 37.0 (t
), 121.9(d), 125.6(d).
127、Hd)、 127.6(d)、 127.
8(d)、128.3(d)。127, Hd), 127.6(d), 127.
8(d), 128.3(d).
129.8(d)、 130.4(d)、 131.7
(d)、140.5(d)、140.8(s)。129.8(d), 130.4(d), 131.7
(d), 140.5(d), 140.8(s).
143.8(s)、 155.0<s)、 170
.3(s)。143.8(s), 155.0<s), 170
.. 3(s).
I Rv cm−’ : 2750.1550.
1480゜次に本発明の化合物の有用性を参考例により
具体的に示す。I Rv cm-': 2750.1550.
1480°Next, the usefulness of the compounds of the present invention will be specifically illustrated by reference examples.
参考例1 化合物(V)の血小板凝集阻害作用ウサギの
多血小板血漿においてADP (10−6M)で血小板
凝集を誘導し化合物(V)による凝集阻害活性を光度測
定法により測定した。その結果化合物(V)100Hg
/ mlで60%の活性が見られた。Reference Example 1 Platelet aggregation inhibitory effect of compound (V) Platelet aggregation was induced in rabbit platelet-rich plasma with ADP (10 −6 M), and the aggregation inhibitory activity of compound (V) was measured by photometry. As a result, compound (V) 100Hg
60% activity was found at
これは、対照薬アデノシンと同等の効果である。This effect is equivalent to that of the control drug adenosine.
参考例2 化合物(V)のヒスタミンH2受容体阻害作
用
モルモットの右心房の固有陰性変時作用の非存在下での
自動的な鼓動において、ヒスタミンの変時効果を50%
抑制すると活性ありとする試験において、化合物(■)
5μg/mj!で活性が見られた。Reference Example 2 Histamine H2 receptor inhibitory effect of compound (V) In automatic heartbeat in the absence of intrinsic negative chronotropic action in the right atrium of guinea pigs, the chronotropic effect of histamine was reduced by 50%.
In a test where inhibition is considered to be active, the compound (■)
5μg/mj! Activity was observed in
これは、対照薬シメチジンと同等の効果である。This is an effect comparable to that of the control drug cimetidine.
参考例3 化合物(■)の陽性変力作用モルモットの
左心房を電気刺激し、収縮力を測定し、増加率が40%
以上で活性ありとする試験において化合物(■)2.5
μg/m1で46%の収縮力増加が見られた。これは対
照薬アムリノンの40倍の効果である。Reference Example 3 Positive inotropic effect of compound (■) The left atrium of a guinea pig was electrically stimulated, the contractile force was measured, and the increase rate was 40%.
Compound (■) 2.5% in the test showing activity.
A 46% increase in contractile force was observed at μg/ml. This is 40 times more effective than the control drug amrinone.
参考例4 化合物(X)の陽性変力作用・化合物(X
)で参考例3と同様に試験した。化合物(X)1Hg/
mIlで73%の収縮力増加が見られた。これは対照薬
アムリノンの100倍の効果である。Reference example 4 Positive inotropic effect of compound (X)
) was tested in the same manner as in Reference Example 3. Compound (X) 1Hg/
A 73% increase in contractile force was observed with mIl. This is 100 times more effective than the control drug amrinone.
参考例5 化合物(X)の抗浮腫作用ラットに化合物
(X)を経口投与し、1時間後に足跋にカラゲニン(0
,1n+j!、1%懸濁液)を投与した。カラゲニン投
与3時間後に、カラゲニン誘導の足踵浮腫が30%以上
抑制されるとき活性ありとする。この試験において化合
物(X)50mg/kgで35%の抑制が見られた。こ
れは対照薬フェニルブタシンと同等の効果である。Reference Example 5 Anti-edema effect of compound (X) Compound (X) was orally administered to rats, and 1 hour later, carrageenin (0
,1n+j! , 1% suspension) was administered. Activity is determined when carrageenan-induced heel edema is suppressed by 30% or more 3 hours after carrageenan administration. In this test, 35% inhibition was observed at 50 mg/kg of Compound (X). This effect is equivalent to that of the control drug phenylbutacin.
処理して誘導した血小板凝集を50%以上阻害するとき
活性ありとする。この試験において化合物(Vl)10
0μg/■で、活性が見られた。これは対照薬アデノシ
ンと同等の効果である。Activity is determined when platelet aggregation induced by treatment is inhibited by 50% or more. In this test, compound (Vl) 10
Activity was observed at 0 μg/■. This effect is equivalent to that of the control drug adenosine.
また、ウサギの多血小板血漿にアラキドン酸ナトリウム
(50μg/mg)を添加して、血小板凝集を誘導し、
これに被験物質を加え血小板凝集を50%以上阻害する
とき、活性ありとする。この試験において、化合物(V
l)2.5μg/mβで活性が見られた。In addition, sodium arachidonate (50 μg/mg) was added to rabbit platelet-rich plasma to induce platelet aggregation,
When the test substance is added to this and inhibits platelet aggregation by 50% or more, it is considered to be active. In this test, the compound (V
l) Activity was observed at 2.5 μg/mβ.
これは、対照薬アスピリンと同等の効果である。This is an effect comparable to that of the control drug aspirin.
参考例7 化合物(VI)の気管支拡張作用摘出潅流
モルモット肺標本をメタコリン0.05μg7mlで予
め収縮させておく、これに被験物質を注入しタイロード
液の流速が50%増加するとき、活性ありとする。この
試験において、化合物(VI)100μg/+nj!で
活性が見られた。Reference Example 7 Bronchodilatory effect of Compound (VI) A perfused isolated guinea pig lung specimen was pre-deflated with 0.05 μg 7 ml of methacholine. When the test substance was injected into this and the flow rate of Tyrode's solution increased by 50%, activity was determined. do. In this test, compound (VI) 100 μg/+nj! Activity was observed in
これは、対照薬アミノフィリンと同等の効果である。This effect is equivalent to that of the control drug aminophylline.
参考例8 化合物(Xlll)の血小板凝集阻害作用
ウサギの多血小板血漿を、予めアラキドン酸ナトリウム
(50μg/mA)を添加して、血小板凝集を透導し、
これに被験物質を加え、血小板凝集を50%以上阻害す
るとき、活性ありとする。Reference Example 8 Platelet aggregation inhibitory effect of compound (Xlll) Rabbit platelet-rich plasma was preliminarily added with sodium arachidonate (50 μg/mA) to induce platelet aggregation.
When the test substance is added to this and inhibits platelet aggregation by 50% or more, it is determined to be active.
この試験において、化合物(XI[I)1.0μg7m
Rで活性が見られた。これは対照薬アスピリンの2.5
倍の活性である。In this test, compound (XI[I) 1.0 μg 7 m
Activity was observed in R. This is 2.5 of the control drug aspirin.
It is twice as active.
参考例9 化合物(XII[)の腸管平滑筋収縮阻害
許艮
モルモットの回腸を32℃の生理食塩水中で電気刺激を
与えて収縮させ、この収縮を50%以上阻害するとき、
活性ありとする。Reference Example 9 Inhibition of Intestinal Smooth Muscle Contraction by Compound (XII[)] When the ileum of a guinea pig is contracted by electrical stimulation in physiological saline at 32°C, and this contraction is inhibited by 50% or more,
It is assumed that there is activity.
この試験において化合物(XIII)0.5μg/n+
4!で活性が見られた。これは対照薬パパベリンの4倍
の活性である。In this test, compound (XIII) 0.5 μg/n+
4! Activity was observed in This is four times more active than the control drug papaverine.
また、モルモットの回腸を32℃の生理食塩水中でアセ
チルコリン(0,1μg/m1)を添加して収縮させ、
この収縮を80%以上阻害するとき、抗コリン活性あり
とする。In addition, the ileum of a guinea pig was contracted in physiological saline at 32°C by adding acetylcholine (0.1 μg/ml).
When this contraction is inhibited by 80% or more, anticholinergic activity is determined.
この試験において化合物(XI[[)0.5μg/ml
で活性が見られた。これは対照薬アトロピンの5分の1
の活性である。In this test, the compound (XI [[) 0.5 μg/ml
Activity was observed in This is one-fifth of the control drug atropine.
activity.
Claims (7)
表等があります▼または、 ▲数式、化学式、表等があります▼ (ただし、R^2は水素又は低級アルキル基、R^3及
びR^4は飽和又は不飽和の低級アルキル基、アミノ基
又はアリール基である)を示す〕の2−キノリルメチル
=スルフィド誘導体。(1) General formula (I): ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I)
There are tables, etc. ▼ or ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ (However, R^2 is hydrogen or a lower alkyl group, R^3 and R^4 are saturated or unsaturated lower alkyl groups, amino groups, 2-quinolylmethyl sulfide derivative of ] which is an aryl group.
びR^4は飽和又は不飽和の低級アルキル基、アミノ基
、又はアリール基である)の化合物とを極性溶媒中で反
応せしめることを特徴とする、2−キノリルメチル=ス
ルフィド誘導体の製造方法。(2) 2-chloromethylquinoline and general formula (III) ▲Mathematical formulas, chemical formulas, tables, etc.▼(III) (However, R^2 is hydrogen or a lower alkyl group, R^3 and R^4 are saturated or an unsaturated lower alkyl group, amino group, or aryl group) in a polar solvent.
らなる群から選んだ少なくとも1つの溶媒であることを
特徴とする特許請求の範囲(2)記載の2−キノリルメ
チル=スルフィド誘導体の製造方法。(3) The method for producing a 2-quinolylmethyl sulfide derivative according to claim (2), wherein the polar solvent is at least one solvent selected from the group consisting of methanol, ethanol, and acetone.
うことを特徴とする特許請求の範囲(2)記載の2−キ
ノリルメチル=スルフィド誘導体の製造方法。(4) The method for producing a 2-quinolylmethyl sulfide derivative according to claim (2), wherein the reaction is carried out at room temperature or by heating and stirring.
化学式、表等があります▼を示す。)の化合物とを極性
溶媒中で反応せしめることを特徴とする、2−キノリル
メチル=スルフィド誘導体の製造方法。(5) 2-Chloromethylquinoline and General formula (IV) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(IV) (In the formula, R^4 is -NH-CH_2-CH_2, ▲Mathematical formula,
There are chemical formulas, tables, etc. Showing ▼. ) in a polar solvent.
らなる群から選んだ少なくとも1つの溶媒であることを
特徴とする特許請求の範囲(5)記載の2−キノリルメ
チル=スルフィド誘導体の製造方法。(6) The method for producing a 2-quinolylmethyl sulfide derivative according to claim (5), wherein the polar solvent is at least one solvent selected from the group consisting of methanol, ethanol, and acetone.
特徴とする特許請求の範囲(5)記載の2−キノリルメ
チル=スルフィド誘導体の製造方法。(7) The method for producing a 2-quinolylmethyl sulfide derivative according to claim (5), wherein the reaction is carried out by stirring at room temperature.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61-230426 | 1986-09-29 | ||
JP23042686 | 1986-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63183563A true JPS63183563A (en) | 1988-07-28 |
Family
ID=16907708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP19743587A Pending JPS63183563A (en) | 1986-09-29 | 1987-08-07 | 2-quinolylmethyl=sulfide derivative and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63183563A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
-
1987
- 1987-08-07 JP JP19743587A patent/JPS63183563A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022034121A1 (en) | 2020-08-11 | 2022-02-17 | Université De Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH649527A5 (en) | 1,2-DIAMINOCYCLOBUTEN-3,4-DIONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS. | |
CH648027A5 (en) | GUANIDINOTHIAZOL COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PREPARATION OF MEDICINAL PRODUCTS. | |
Manley et al. | Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas | |
DE102004008141A1 (en) | Guanidine compounds and their use as binding partners for 5-HT5 receptors | |
CH626883A5 (en) | ||
JPS6320231B2 (en) | ||
WO2007022947A2 (en) | 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors | |
EP0041215B1 (en) | Imidazoazolalkenyl carboxamides, intermediates for their preparation, their preparation and their use as medicaments | |
CH641460A5 (en) | AZOLOPYRIMIDINONE AND RELATED COMPOUNDS. | |
CH428747A (en) | Process for the production of new urea and thiourea derivatives | |
LU82000A1 (en) | NEW THIAZOLYL METHYL THIODERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS | |
EP1173176B1 (en) | Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity | |
EP0004561B1 (en) | Urea and amide derivatives, their preparation, pharmaceuticals containing them and their use for preparing pharmaceutical compositions | |
US4490393A (en) | Thiazolylurea derivatives, a process for preparing same and a pharmaceutical composition containing same | |
JPS63183563A (en) | 2-quinolylmethyl=sulfide derivative and production thereof | |
DE2614189A1 (en) | Analgesic, antiinflammatory and antipyretic thiazolyl-urea derivs. - prepd. by reacting an isocyanato-carboxylic acid cpd. with an amino-or hydrazino-thiazole | |
EP0065658A2 (en) | Utilisation of sulfenamides as antilipoxygenase agents, and medicaments containing them | |
DE1445505B2 (en) | 2-PHENYLAMINO-1,3-DIAZACYCLOPENTENE- (2) SUBSTITUTED IN THE PHENYL CORE | |
DE1934392A1 (en) | New thioamides and processes for their preparation | |
DE3639466A1 (en) | NEW PYRROLO-BENZIMIDAZOLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | |
CA1267412A (en) | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine h2-receptor antagonist activity | |
AT362386B (en) | METHOD FOR PRODUCING NEW GUANIDINE DERIVATIVES AND THEIR ACID ADDITION SALTS | |
DE1670945C3 (en) | Arylsulfonylureas, process for their preparation and oral anti-diabetic drug | |
AT230891B (en) | Process for the production of new sulfonamides and their salts | |
US3284498A (en) | Substituted benzene sulfonyl urea |